Zydus Lifesciences Limited (IN:ZYDUSLIFE)
:ZYDUSLIFE
ZYDUSLIFE Stock Chart & Stats
₹921.80
-₹19.40(-1.94%)
At close: 4:00 PM EST
₹921.80
-₹19.40(-1.94%)
Day’s Range― - ―
52-Week Range₹797.05 - ₹1,059.00
Previous CloseN/A
Volume1.39M
Average Volume (3M)33.86K
Market Cap
₹869.64B
Enterprise Value₹938.17B
Total Cash (Recent Filing)₹70.69B
Total Debt (Recent Filing)₹96.36B
Price to Earnings (P/E)22.1
Beta0.56
Next Earnings
May 15, 2026EPS Estimate
8.2Next Dividend Ex-DateN/A
Dividend Yield1.19%
Share Statistics
EPS (TTM)10.03
Shares Outstanding1,006,234,000
10 Day Avg. Volume33,597
30 Day Avg. Volume33,862
Financial Highlights & Ratios
PEG Ratio1.05
Price to Book (P/B)3.69
Price to Sales (P/S)3.80
P/FCF Ratio17.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,015.00Price Target Upside10.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)40.7
Revenue Forecast (FY)₹288.39B
Bulls Say, Bears Say
Bulls Say
High Margins & ProfitabilitySustained high gross and operating margins indicate durable cost structure and pricing power across its portfolio. This margin profile supports reinvestment in R&D, funds marketing for branded products, and provides a buffer versus pricing pressure in generics, aiding medium‑term profitability.
Strong Cash GenerationRobust conversion of earnings into cash and very high free cash flow growth provide durable financial flexibility. Strong cash generation funds capex, R&D, potential bolt‑on deals, dividends and deleveraging, reducing reliance on external financing over the next several quarters.
Low Leverage And Strong Equity BaseVery low leverage and a substantial equity base give Zydus financial resilience and capacity to fund growth initiatives. High ROE shows effective capital use, enabling sustained investment into complex generics, APIs and branded portfolios without materially increasing financial risk.
Bears Say
High Total Liabilities (absolute)Although leverage ratios are low, a high absolute level of total liabilities can still constrain flexibility if liabilities are short‑dated or linked to working capital. This raises medium‑term refinancing, covenant or cash‑flow timing risks during stress or large investment needs.
Earnings Growth Lags RevenueRevenue is expanding faster than EPS, suggesting margin compression, higher operating investments or noncash items reducing attributable earnings growth. If this gap persists, it may limit per‑share profitability gains and shareholder returns over the next several quarters.
Exposure To Generics Approvals And CompetitionMaterial reliance on regulated‑market generics creates structural revenue visibility risk: regulatory approvals, launch sequencing and intense price competition can delay or diminish returns. This dependency can weigh on medium‑term growth and margin predictability.
Zydus Lifesciences Limited News
ZYDUSLIFE FAQ
What was Zydus Lifesciences Limited’s price range in the past 12 months?
Zydus Lifesciences Limited lowest stock price was ₹797.05 and its highest was ₹1059.00 in the past 12 months.
What is Zydus Lifesciences Limited’s market cap?
Zydus Lifesciences Limited’s market cap is ₹869.64B.
When is Zydus Lifesciences Limited’s upcoming earnings report date?
Zydus Lifesciences Limited’s upcoming earnings report date is May 15, 2026 which is in 41 days.
How were Zydus Lifesciences Limited’s earnings last quarter?
Zydus Lifesciences Limited released its earnings results on Feb 09, 2026. The company reported ₹10.03 earnings per share for the quarter, missing the consensus estimate of ₹10.832 by -₹0.802.
Is Zydus Lifesciences Limited overvalued?
According to Wall Street analysts Zydus Lifesciences Limited’s price is currently Undervalued.
Does Zydus Lifesciences Limited pay dividends?
Zydus Lifesciences Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 1.19%. See more information on Zydus Lifesciences Limited dividends here
What is Zydus Lifesciences Limited’s EPS estimate?
Zydus Lifesciences Limited’s EPS estimate is 8.2.
How many shares outstanding does Zydus Lifesciences Limited have?
Zydus Lifesciences Limited has 1,006,234,000 shares outstanding.
What happened to Zydus Lifesciences Limited’s price movement after its last earnings report?
Zydus Lifesciences Limited reported an EPS of ₹10.03 in its last earnings report, missing expectations of ₹10.832. Following the earnings report the stock price went up 3.97%.
Which hedge fund is a major shareholder of Zydus Lifesciences Limited?
Currently, no hedge funds are holding shares in IN:ZYDUSLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.
ZYDUSLIFE Stock 12 Month Forecast
Average Price Target
₹1,015.00
▲(10.11% Upside)
Technical Analysis
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Mankind Pharma Ltd.
―
Torrent Pharmaceuticals Ltd
―